Amanta Healthcare Limited, a leading pharmaceutical manufacturer, is set to launch its initial public offering (IPO) on September 1, 2025. The book-building issue consists entirely of a fresh issue of 1 crore equity shares with a face value of ₹10 each. The IPO will close on September 3, 2025, with allotments expected on September 4 and a tentative listing date scheduled for September 8, 2025 on both BSE and NSE.
IPO Details
-
IPO Open Date: September 1, 2025
-
IPO Close Date: September 3, 2025
-
Allotment Date: September 4, 2025
-
Tentative Listing: September 8, 2025
-
Issue Size: 1,00,00,000 shares (₹[.] crore)
-
Price Band: [.] to [.] per share
-
Face Value: ₹10 per share
-
Issue Type: Book-building, Fresh Capital
-
Listing At: BSE, NSE
-
Lot Size: [To be announced]
-
Pre-Issue Shares: 2,88,29,351
-
Promoters: Bhavesh Patel, Vishal Patel, Jayshreeben Patel, Jitendra Kumar Patel, and Milcent Appliances Pvt. Ltd.
-
Pre-Issue Holding: 85.60%
Reservation:
-
QIBs: Not more than 50%
-
Retail: Not less than 35%
-
NIIs: Not less than 15%
Lead Manager: Beeline Capital Advisors Pvt. Ltd.
Registrar: MUFG Intime India Pvt. Ltd.
About Amanta Healthcare
Incorporated in 1994, Amanta Healthcare specializes in sterile liquid pharmaceuticals, particularly parenteral products packaged using advanced Aseptic Blow-Fill-Seal (ABFS) and Injection Stretch Blow Moulding (ISBM) technologies. The company also manufactures a range of medical devices.
Its portfolio includes:
-
IV fluids & diluents
-
Ophthalmic solutions & respiratory care products
-
Irrigation solutions, first-aid products, and eye lubricants
Amanta operates through three key business units:
-
National Sales – distributed via 320 stockists across India.
-
International Sales – exports branded products to 21 countries.
-
Product Partnerships – with Indian and global pharma companies.
The company has over 45 generic products, with regulatory approvals across 19 countries including the UK, Africa, and Latin America. As of March 31, 2025, Amanta employs 1,718 staff across its formulation, development, and quality labs.
Competitive Strengths
-
Established player in pharmaceutical formulations.
-
Diverse product portfolio with global demand.
-
Advanced manufacturing technologies for sterile liquids.
-
Strong domestic and international presence.
-
Experienced management team with a large skilled workforce.
Should You Invest in Amanta Healthcare IPO?
Opportunities:
-
The company operates in a defensive and growing sector — healthcare and pharmaceuticals.
-
Strong export footprint across 21 countries, reducing dependency on domestic sales.
-
Expansion potential through new product launches and global partnerships.
-
Experienced promoters with over two decades of industry expertise.
Risks to Consider:
-
IPO price band has not yet been finalized, making valuation clarity limited.
-
Pharma is a highly regulated industry, and compliance risks can affect profitability.
-
Heavy competition from domestic and multinational pharmaceutical firms.
-
Dependence on global demand exposes the company to currency and geopolitical risks.
Conclusion
The Amanta Healthcare IPO offers investors exposure to a diversified pharmaceutical company with robust manufacturing capabilities and a strong global presence. While the growth prospects are promising, investors should carefully evaluate the final pricing and regulatory environment before subscribing. For those seeking long-term opportunities in the healthcare sector, Amanta Healthcare may be worth considering.
